A recent clinical trial showed no beneficial effects of statin treatment in patients with Alzheimer disease (AD) and normal cholesterol levels. Other studies show that the effects of statins can vary depending on cholesterol levels and stage of disease, so statins should not be ruled out as an AD therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients
Alzheimer's Research & Therapy Open Access 18 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sano, M. et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77, 556–563 (2011).
Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP III final report). NIH National Heart Blood and Lung Institute [online], (2002).
Sparks, D. L. et al. Atorvastatin for the treatment of mild-to-moderate Alzheimer's disease: preliminary results. Arch. Neurol. 62, 753–757 (2005).
Sparks, D. L. et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 5, 416–421 (2008).
Sparks, D. L. et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener. Dis. 7, 183–186 (2010).
Bettermann, K. et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J. Stroke Cerebrovasc. Dis. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002.
Feldman, H. H. et al. Randomized controlled trial of atorvastatin in mild-to-moderate Alzheimer's disease: LEADe. Neurology 74, 956–964 (2010).
Feldman, H. H. et al. The LEADe Study: a randomized controlled trial investigating the effect of atorvastatin on cognitive and global function in patients with mild to moderate AD receiving background therapy of donepezil [abstract LBS.005]. Neurology 71, 54 (2008).
Sparks, D. L. et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in AD: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta. Neurol. Scand. 114, 3–7 (2006).
Sparks, D. L. et al. The atorvastatin/donepezil in Alzheimer's disease (LEADe) study: effect of atorvastatin on Alzheimer's disease progression by ApoE4 genotype. Presented at the International Conference on Alzheimer's Disease (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sparks, D. Statins in the treatment of Alzheimer disease. Nat Rev Neurol 7, 662–663 (2011). https://doi.org/10.1038/nrneurol.2011.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.165
This article is cited by
-
Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients
Alzheimer's Research & Therapy (2016)
-
Evaluation of Lovastatin Effects on Expression of Anti-apoptotic Nrf2 and PGC-1α Genes in Neural Stem Cells Treated with Hydrogen Peroxide
Molecular Neurobiology (2014)
